跳转到内容

用户讨论:Fghostyun6

页面内容不支持其他语言。
维基百科,自由的百科全书
您好,Fghostyun6!欢迎加入维基百科!

感谢您对维基百科的兴趣与贡献,希望您会喜欢这里。除了欢迎辞以外,也请您了解以下重要文章:

政策
政策
GNU
GNU
版权问题解答
贡献内容必须是您所著或获得授权
并同意在CC-by-sa-3.0和GFDL条款下发布
手册
手册
问号
问号
有问题?请到互助客栈询问,或在我的对话页提出。别忘记:讨论后要签名,方式之一是留下4个波浪纹“ ~~~~ ”。
If you have any questions about the Chinese Wikipedia, please leave a message here. Thank you for visiting!

我是欢迎您的维基人: 2011年7月4日 (一) 10:23 (UTC)(via Alexbot Operate via Alexsh)[回复]


您创建的条目User:Fghostyun6可能侵犯版权

[编辑]

您创建的条目被认为同他人的文字雷同快去看看怎么回事。

维基百科只接受公有领域知识共享 署名-相同方式共享 3.0协议的内容,如果希望文字内容继续留存在维基百科上,请:

  • 捐献版权 - 适用于文字原创者或版权持有者;
  • 请求版权许可 - 适用于复制他人内容,且希望继续使用者;
  • 重写 - 适用于复制他人内容,且无法获得授权者;
  • 申诉 - 这可能只是个误会。

谢谢您的合作。—Symplectopedia (留言) 2011年7月5日 (二) 09:21 (UTC)[回复]

膀胱癌肿瘤标志物检测试剂盒Urinary Bladder Neoplasms Molecular Marker Detection Kit

[编辑]

膀胱癌肿瘤分子标志物检测试剂盒 Urinary Bladder Neoplasms Molecular Marker Detection Kit

[Source: http://www.biopharmsoft.com]


Description: The kit provides a means of performing Urinary Bladder Neoplasms detection method based on kinase activity assay. This kit includes Streptavidin Coated Plates and specific SubstratePeptides (biotinylated peptide substrates) for detection of the activity of EGFR, FGFR3 and SRC which indicate the prognosis of Urinary Bladder Neoplasms.


Label of Substrate-Peptides: Biotinylated.


Quality Control: The substrate peptide was selected using our Urinary Bladder Neoplasms Diagnosis Kit. The quality of the biotinylated peptide was evaluated by reverse-phase HPLC and by mass spectrometry.


Storage:


Store at 4 °C, Avoid Freeze.


Background:


EGFR (epidermal growth factor receptor) exists on the cell surface and is activated by binding of its specific ligands, including epidermal growth factor and transforming growth factor α (TGFα) (note, a full list of the ligands able to activate EGFR and other members of the ErbB family is given in the ErbB article). ErbB2 has no known direct activating ligand, and may be in an activated state constitutively or become active upon heterodimerization with other family members such as EGFR. Upon activation by its growth factor ligands, EGFR undergoes a transition from an inactive monomeric form to an active homodimer – although there is some evidence that preformed inactive dimers may also exist before ligand binding. FGFR3 is a member of the fibroblast growth factor receptor family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein would consist of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. Src (pronounced "sarc" as it is short for sarcoma) is a proto-oncogene encoding a tyrosine kinase originally discovered by J. Michael Bishop and Harold E. Varmus, for which they won the 1989 Nobel Prize in Physiology or Medicine. It belongs to a family of non-receptor tyrosine kinases called Src family kinases. The discovery of Src family proteins has been instrumental to the modern understanding of cancer as a disease where normally healthy cellular signalling has gone awry.